Is Nebracetam safe for human use?

It is unknown: as of 2023 no human clinical trial had ever been run, so its safety profile is uncharacterized. Only preclinical (rat and in vitro) data exist, so it cannot be recommended for human use.

How does it differ from other racetams?

Unlike most racetams, Nebracetam acts as a direct M1 muscarinic acetylcholine receptor agonist rather than only through glutamatergic or indirect cholinergic routes. This makes it one of the rarest, most receptor-specific members of the cholinergic racetam class.

Can I buy Nebracetam as a supplement?

Effectively no: it is an investigational compound never approved as a drug or supplement anywhere, and it appears in the literature only as an obscure, reference-level molecule.

EmergingResearch compoundReference only

Nebracetam

Name: Nebracetam
Creator: MolekulaX

Cholinergic racetam: direct M1 muscarinic agonist, backed only by preclinical (rat, in vitro) data.

NootropicRacetamCholinergicRacetamAcetylcholineAcetylcholineDopamineSerotonin

Pharmacology

ClassRacetam · Acetylcholine

Primary targetM1 muscarinic acetylcholine receptor agonist

Targets3 receptor targets

Half-lifeN/A (no human data)

OnsetN/A (no human pharmacokinetic data)

EvidenceReference only

Affected systemsAcetylcholineDopamineSerotonin

Contents

WHAT IS NEBRACETAM?

Detailed overview

Nebracetam (development code WEB 1881 FU) is a pyrrolidinone-scaffold racetam from Japanese research, studied primarily as an M1 muscarinic acetylcholine receptor agonist. In rat models it increased acetylcholine synthesis and release, supported high-affinity choline uptake, and showed modest neuroprotection after cerebral ischemia and microsphere embolism (PMID 2041225, 2385003, 9179389). A 1991 in vitro experiment in a human Jurkat cell line suggested it may act as a human M1 receptor agonist, but no human clinical trials had been conducted as of 2023. The compound therefore remains a purely reference-level, preclinical curiosity.

Mechanism

M1 muscarinic agonist + cholinergic

Evidence

Preclinical (rat, in vitro)

Half-life

N/A (no human data)

Legal status

Investigational (not marketed)

Receptor profile

M1 muscarinic ACh receptorStrong
High-affinity choline uptake / ACh releaseModerate
Neuroprotection (cerebral ischemia)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 5

No human safety data exist; the following are theoretical risks inferred from the cholinergic (muscarinic agonist) mechanism, not observed effects
Nausea, diarrhea or abdominal cramping, typical of muscarinic overstimulation
Increased salivation, sweating or lacrimation (peripheral cholinergic effects)
Headache, as with many other racetams
Theoretical cardiovascular risk: bradycardia or a drop in blood pressure can occur with muscarinic agonism

Contraindications · 6

Pregnancy and breastfeeding: no safety data, should be avoided
Not studied for human use: with no clinical data it is not recommended for human consumption and should be treated only as a research reference
Bradycardia or cardiac conduction disorder: muscarinic agonism may further slow heart rate
Asthma or COPD: muscarinic activation may trigger bronchoconstriction
Peptic ulcer or gastrointestinal disease: increased gastric acid and motility are possible
Concurrent anticholinergic medications: they may mutually blunt each other's effects

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

Japanese Journal of Pharmacology (1991)

Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist

Kitamura Y, Kaneda T, Nomura Y

PMID: 2041225Open

Japanese Journal of Pharmacology (1990)

Evaluation of the neuroprotective action of WEB 1881 FU on hypoglycemia/hypoxia-induced neuronal damage using rat striatal slices

Koizumi S, Kataoka Y, Shigematsu K, Niwa M, Ueki S

PMID: 2385003Open

British Journal of Pharmacology (1997)

Effects of delayed treatment with nebracetam on neurotransmitters in brain regions after microsphere embolism in rats

Takeo S, Hayashi H, Miyake K, Takagi K, Tadokoro M, Takagi N, Oshikawa S

PMID: 9179389Open

FAQ

Cholinergic racetam: direct M1 muscarinic agonist, backed only by preclinical (rat, in vitro) data.

Have a question about Nebracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic

FormulaC12H16N2O

UpdatedJuly 9, 2026

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: July 9, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.